Business Context and Reporting Period
Company: LifeMD, Inc. (LFMD)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: LifeMD is a direct-to-patient telehealth company operating a vertically integrated platform combining proprietary technology, an affiliated 50-state provider network, and a wholly-owned commercial pharmacy. The company serves approximately 328,000 active patient subscribers across primary care, weight management, men's and women's health, and dermatology. Approximately 95% of revenue is derived from recurring subscriptions.
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Telehealth Revenue (Net) | $194.1 million | $154.8 million |
| Gross Profit | $166.3 million | $133.4 million |
| Gross Margin | 85.7% | 86.2% |
| Operating Loss (Continuing Ops) | $(7.7) million | $(20.4) million |
| Net Loss (Continuing Ops) | $(10.2) million | $(23.2) million |
| Net Income (Total, incl. Discontinued) | $15.6 million | $(20.9) million |
| Net Income Attributable to Common Stockholders | $11.2 million | $(24.5) million |
| Cash and Cash Equivalents | $36.8 million | $32.7 million |
| Working Capital | $10.3 million | $(15.0) million deficit |
| Total Liabilities | $47.3 million | $83.7 million |
| Long-Term Debt | $0 | $9.9 million |
Material Changes vs. Prior Period
- Revenue Growth: Telehealth revenue increased 25% year-over-year, driven by a $45.6 million increase in subscription revenue.
- Profitability Improvement: Operating loss from continuing operations narrowed significantly from $20.4 million in 2024 to $7.7 million in 2025. The company reported a net loss from continuing operations of $10.2 million, compared to $23.2 million in the prior year.
- Discontinued Operations: The company sold its majority interest in WorkSimpli Software LLC in November 2025. This resulted in a gain on sale of $21.3 million (net of tax), turning the full-year consolidated result from a net loss to a net income of $15.6 million.
- Debt Reduction: The company fully repaid its $40 million Avenue Credit Facility in August 2025, incurring a $1.2 million loss on debt extinguishment. As of year-end, the company had no outstanding long-term debt.
- Working Capital: Working capital improved from a deficit of $15.0 million to a positive $10.3 million, primarily due to the reduction of current liabilities associated with the debt repayment and the sale of discontinued operations.
Guidance, Outlook, and Risks
Management Commentary and Outlook
- Liquidity: Management expects existing cash of $36.8 million to fund operations for at least the next 12 months. The company has $44.6 million remaining availability under its At-The-Market (ATM) Sales Agreement.
- Insurance Expansion: The company expanded insurance acceptance to cover approximately 112 million lives as of December 31, 2025, with plans to expand to 230 million lives by June 1, 2026.
- Strategic Focus: The sale of WorkSimpli positions the company as a pure-play healthcare entity. Future investments will focus on growing the provider network, pharmacy fulfillment, and AI-enabled operational systems.
Risks and Contingencies
- Internal Controls: The company identified material weaknesses in internal control over financial reporting (ICFR) as of December 31, 2025. These relate to revenue recognition (agent vs. principal), segregation of duties, and IT general controls. Previously issued financial statements were revised to correct immaterial errors.
- Regulatory Environment: The company faces significant regulatory risks regarding compounded medications (specifically GLP-1s), FDA enforcement actions, and evolving state privacy laws. The "One Big Beautiful Bill Act" (OBBBA) enacted in July 2025 may impact future government payments.
- Legal Proceedings: The company is subject to a putative securities class action lawsuit filed in August 2025 and related shareholder derivative complaints. A preliminary class action settlement regarding data privacy was approved in September 2025, with a liability of approximately $1.1 million recorded.
- Profitability: The company has not yet achieved profitability from continuing operations and anticipates increasing expenses as it scales.
Investor Verification Checklist
- Discontinued Operations Impact: Verify the sustainability of the net income figure, which is heavily influenced by the one-time $21.3 million gain from the sale of WorkSimpli.
- Internal Control Remediation: Monitor the progress of remediation plans for the identified material weaknesses in ICFR, particularly regarding revenue recognition and IT controls.
- Debt-Free Status: Confirm the company's ability to maintain liquidity without the previous credit facility, relying on operating cash flow and ATM equity sales.
- Regulatory Compliance: Assess the impact of FDA enforcement actions on compounded drugs and the company's shift to branded medication access via insurance.
- Legal Exposure: Track the status of the securities class action lawsuit and the finalization of the data privacy settlement.